Progesterone-related diabetes mellitus (PRDM) in dogs is known for its particular potential for diabetes remission. This narrative review aims to provide relevant detailed information on (1) the canine estrus cycle and its impact on canine diabetes mellitus (CDM) etiology and management, (2) the role of pyometra as a further cause of insulin resistance, and (3) useful individual therapeutic and preventive strategies. PRDM is recognized due to diestrus, exogenous progestogen exposure, pregnancy, and P4-production ovarian dysfunction. Pyometra represents additional inflammatory and septic negative influence on insulin sensitivity, and its diagnosis associated with CDM is therapeutically challenging. The estrus cycle’s hormone fluctuations seem to modulate peripheric insulin sensibility by influencing insulin receptor (IR) affinity and its binding capacity, as well as modulating tyrosine kinase activity. Pyometra was shown to negatively influence IR compensatory mechanisms to insulin resistance causing glucose intolerance. Spaying and pregnancy termination may cause diabetes remission in PRDM cases in a median time of 10 days (1–51). Pharmacological annulment of progesterone effects may benefit patients unable to undergo surgery; however, remission chances are virtually null. The ALIVE (Agreeing Language in Veterinary Endocrinology) project proposed new criteria for CDM diagnoses and subclinical diabetes recognition. These new concepts may increase the frequency of a PRDM diagnosis and, even more, its relevance. Spaying represents a preventive measure against pyometra and PRDM that should be individually assessed in light of its recognized benefits and harms.
Portable blood glucose meters (PBGMs) are essential for detecting glycemic disorders. In Brazil, veterinary devices are scarce, and human devices are used as an alternative. This study evaluated the accuracy of three human glucometers: Accu-Chek Guide® (ACG) and Accu-Chek Guide Me® (ACGM) (Roche), and EcoCheck® (EC) (Eco Diagnóstica). A total of 419 glycemic samples were collected and compared to the glucose oxidase method (GOM), considered the gold standard. Despite a strong positive correlation compared to the GOM (ACG r = 0.96; ACGM r = 0.9; EC r = 0.89; P <0.0001), when evaluated by the criteria defined by ISO15197:2013 for analytical precision, no PG obtained 99% of the readings within the range of +/- 15 for glucose levels 100mg/dL (ACG = 57.9%, ACGM = 47.9%, and EC = 28.4%). ACG was the only PG that fully met the clinical precision criteria according to ISO15197:2013, with 100% of its measurements in zones A+B of the error grid. Despite analytical inaccuracy, ACG PBGM proved to be the best among the devices tested in this study for use in dogs with whole blood samples, not generating any negative impact on animal health.
Correlations among estrus cycle, pyometra, and canine diabetes mellitus (CDM) have been described since the late 1950s, and substantial progress in understanding mechanisms beyond was achieved nowadays. Progesterone-related diabetes mellitus (PRDM) in dogs is known for its particular potential for diabetes remission. Thus, a deep understanding of the physiopathological aspects involved is crucial to postulate treatment guidelines to improve the PRDM remission rate, as well as to inform preventive measures. This narrative review aims to provide relevant detailed information on 1) canine estrus cycle and its impact on CDM etiology and management, 2) the role of pyometra as a further cause of insulin resistance, and 3) useful individual therapeutic and preventive strategies. Pharmacological annulment of progesterone effects, as well as inflammatory and progesterone-related conditions resolution in association with adequate exogenous insulin therapy, and residual beta cell function, are key aspects to achieve remission, or at least to improve diabetic clinical control. In this way, spaying should be considered mandatory in most PRDM cases. Preventive measures against CDM can include spaying recommendations; however, individual-based recommendations should be considered since castration may be associated with some long-term health issues.
Portable blood glucose meters (PBGMs) are essential for detecting glycemic disorders. In Brazil, veterinary devices are scarce, and human devices are used as an alternative. This study evaluated the accuracy of three human glucometers: Accu-Chek Guide® (ACG), Accu-Chek Guide Me® (ACGM) (Roche), and EcoCheck® (EC) (Eco Diagnóstica). A total of 419 glycemic samples were collected and compared to the glucose oxidase method (GOM), which is considered to be the gold standard. Despite a strong positive correlation compared to the GOM (ACG r = 0.96; ACGM r = 0.9; EC r = 0.89; p < 0.0001), when evaluated by the criteria defined by ISO 15197:2013 for analytical precision, no PG obtained 99% of the readings within the range of +/− 15 for glucose levels < 100 mg/dL and +/− 15% for glucose levels > 100 mg/dL (ACG = 57.9%, ACGM = 47.9%, and EC = 28.4%). ACG was the only PG that fully met the clinical precision criteria according to ISO 15197:2013, with 100% of its measurements in Zones A+B of the error grid. Despite analytical inaccuracy, the ACG PBGM proved to be the best among the devices tested in this study for use in dogs with whole blood samples, not generating any negative impact on animal health.
9 October 2026 in Topics in Companion Animal Medicine
Spontaneous hypercortisolism (HC), a prevalent endocrinopathy among elderly dogs, is mainly confirmed by the low dexamethasone dose suppression test (LDDST). However, its diagnostic sensitivity in Brazil is anecdotally reported low compared with published literature. Medical treatment with mitotane was the rule over decades in Brazil but has been progressively substituted by trilostane, an argued safer drug. This work evaluated the LDDST sensitivity and medical treatment efficacy of trilostane and mitotane in dogs treated for HC in Southern Brazil. The retrospective cohort study included 122 dogs treated with trilostane (58.2%) or mitotane (41.8%). Pituitary-dependent HC cases were overrepresented (81.96%). Treatment outcomes (P=0.61) and survival (P=0.16) were similar in response to mitotane or trilostane, with good clinical control achieved in 72.5% and 62.4% of dogs respectively. The LDDST sensitivity in this population was considered lower (77.8%) than reported in the literature with a cutoff of 1.4 µg/dL for 8-hour post-dexamethasone cortisol; however, a suggested 0.8µg/dL cutoff significantly (P=0.01) increased the test sensitivity to 85.2%. Mitotane should still be considered as a medical treatment option for canine HC. Individually reducing the LDDST cutoff in patients with well-documented clinical Cushing´s syndrome diagnosis could be worthwhile.